An adaptive platform trial will test simultaneous amyloid and tau-targeting therapies in asymptomatic, biomarker-positive individuals to accelerate dementia drug development.
Key Takeaways
- Attempting to disrupt the neurodegenerative cascade before permanent cognitive symptoms can manifest
- In the trial, all participants will receive at least one active treatment
- Researchers will add drugs from different, sometimes competing, companies over time